A federal court has delivered its first sentencing in the Kaman Corporation insider trading scandal, marking a pivotal development in one of the most significant financial misconduct cases in recent memory. Jonathan Whitesides, identified as a central figure in the scheme, received a prison sentence today for his involvement in illegal securities trading.
Illicit Gains Preceded Major Corporate Takeover
The illegal trading activity occurred in the days preceding the acquisition of Kaman Corporation by Arcline Investment Management. Court documents reveal that in December 2023, Brent Cranmer, then a manager at a Kaman subsidiary, obtained confidential information about the impending takeover, which was set at $46 per share.
Cranmer subsequently shared these material non-public details with his associate, Jonathan Whitesides, who then passed the information to Daniel McCormick. Acting on this privileged knowledge, both individuals purchased substantial positions in Kaman stock and call options before the acquisition became public knowledge on January 19, 2024.
The financial scale of their illicit activities demonstrates the severity of the violation:
– Whitesides generated approximately $923,000 in illegal profits
– McCormick secured gains totaling about $116,000
– Kaman’s share price surged 101% following the announcement, climbing from $22.43 to $45.05
Should investors sell immediately? Or is it worth buying Kaman?
Regulatory and Legal Proceedings Advance
Throughout 2025, both the U.S. Securities and Exchange Commission and the U.S. Attorney’s Office for the Southern District of New York brought substantial charges against all three participants. Each defendant has pleaded guilty to securities fraud in parallel criminal proceedings.
While Whitesides received his sentence today, Daniel McCormick had already been convicted on September 26. Brent Cranmer, the original source of the confidential information, is scheduled for sentencing on November 10.
Corporate Transition Overshadowed by Scandal
The $1.8 billion acquisition of Kaman by Arcline Investment Management concluded the aerospace company’s nearly eight-decade history as a publicly traded entity. Although shareholders benefited from receiving a substantial premium through the transaction, the process was tainted by the unauthorized disclosure and subsequent illegal trading activities.
Kaman now operates as a privately held company under Arcline’s ownership, maintaining its presence across aerospace, defense, medical, and industrial markets. For the corporation, the judicial outcome brings closure to this damaging episode, serving as a stark reminder about the critical importance of regulatory compliance and sound corporate governance practices.
Ad
Kaman Stock: Buy or Sell?! New Kaman Analysis from October 4 delivers the answer:
The latest Kaman figures speak for themselves: Urgent action needed for Kaman investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 4.
Kaman: Buy or sell? Read more here...